Form 4: Belite Bio Director Sells Shares Under 10b5-1 Plan

Belite Bio Director Chen Wan-Shan reported a sale of American depositary shares under a pre-arranged trading plan.

Summary

• Director Chen Wan-Shan sold 1,100 American depositary shares (ADS) of Belite Bio, Inc. (BLTE).
• The transaction occurred on April 9, 2026.
• The sale was executed at a price of $180.4301 per ADS.
• Following the transaction, the reporting person beneficially owns 9,096 ADS.
• The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the insider sale, despite the transaction being executed under a Rule 10b5-1 plan.

Negatives

• Director sold a significant number of shares, which could be perceived negatively by the market.

Risks

• The sale of shares by a director could indicate a lack of confidence in the company's future prospects, although it was executed under a pre-arranged plan.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a transaction.

Industry Context

StockSavvy.ai notes that insider sales, even under a 10b5-1 plan, are closely watched by the market as they can sometimes signal management's view on the company's valuation or future performance. However, the existence of a pre-arranged plan mitigates concerns about opportunistic selling based on non-public information.

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal, potentially impacting short-term stock sentiment.

Key Dates

Recommendation

The filing reports a routine transaction by a director under a pre-established plan, which does not provide sufficient new information to warrant a buy or sell recommendation. The sale itself is a minor event in the context of the company's overall performance and prospects.

Keywords

Belite Bio, BLTE, Form 4, Insider Trading, Share Sale, 10b5-1 Plan, Director Transaction, SEC Filing